BioCryst's Orladeyo Patent Litigation for 2025
BioCryst Pharmaceuticals is involved in patent litigation concerning its hereditary angioedema (HAE) drug, Orladeyo (berotralstat) [1]. The primary focus of these legal challenges centers on patents that could impact the drug's market exclusivity, potentially opening the door for generic competition [1].
When Could Generic Orladeyo Be Available?
The availability of generic versions of Orladeyo depends on the outcomes of ongoing patent litigation and the expiration dates of key patents. DrugPatentWatch.com tracks these patent statuses and litigation, providing insights into potential market entry timelines for generics [2]. Generally, generic drug entry occurs after patent expiry, but legal challenges can alter these timelines.
What Patents Are Being Challenged?
Specific patents related to Orladeyo's formulation and method of use are reportedly subject to challenges [1]. These challenges often come from generic drug manufacturers seeking to enter the market earlier than patent exclusivity would otherwise allow. Information on the exact patents and their status can be found through patent analytics resources [2].
Why Are Companies Challenging Orladeyo's Patents?
Companies challenge drug patents primarily to gain an earlier entry into the market with their own generic versions of the drug. A successful challenge can significantly impact a drug's revenue stream for the innovator company by reducing the period of market exclusivity.
How Does Orladeyo Work for Hereditary Angioedema?
Orladeyo is a first-in-class, oral, once-daily therapy that selectively inhibits plasma kallikrein [3]. By inhibiting plasma kallikrein, berotralstat prevents the cascade that leads to swelling attacks in individuals with HAE [3].
What Are the Clinical Data for Orladeyo?
Clinical trials have demonstrated Orladeyo's efficacy in reducing the number of HAE attacks [3]. Studies such as APeX-2 showed a statistically significant reduction in the monthly attack rate for patients treated with berotralstat compared to placebo [3].
Who Are BioCryst's Competitors in the HAE Market?
The HAE market includes other treatments, such as injectable therapies and a C1 esterase inhibitor, that compete with Orladeyo [3]. BioCryst faces competition from other pharmaceutical companies with approved HAE therapies.
What Are the Potential Risks and Side Effects of Orladeyo?
Common side effects reported with Orladeyo include gastrointestinal issues such as diarrhea, abdominal pain, and nausea [3]. Patients and healthcare providers consider these potential side effects when evaluating treatment options.
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://www.orladeyo.com/